This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1

This study has been terminated.
(Low/no enrollment. No subjects were enrolled over the past year.)
Information provided by (Responsible Party):
Anandasabapathy, Sharmila, M.D. Identifier:
First received: June 28, 2011
Last updated: January 8, 2016
Last verified: January 2016
The overall objective of this study is to obtain data to evaluate whether high-resolution imaging of the gastrointestinal mucosain vivo can assist clinicians in detecting dysplastic (precancerous) areas. This is an exploratory study of a confocal endoscope designed to evaluate the feasibility of using this FDA-approved device in the endoscopic surveillance of subjects at high-risk for neoplasia in the upper and lower GI tract. The confocal endoscope provides real-time in vivo microscopic images of the mucosa which resemble standard pathology.

Condition Intervention Phase
GERD Barrett's Esophagus Drug: Fluorescein Drug: Proflavine hemisulfate Early Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia - Project 1

Resource links provided by NLM:

Further study details as provided by Anandasabapathy, Sharmila, M.D.:

Primary Outcome Measures:
  • to determine whether tissue is neoplastic or non-neoplastic [ Time Frame: 1 day ]

Enrollment: 67
Study Start Date: June 2009
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fluorescein
Confocal imaging using contrast agent fluorescein
Drug: Proflavine hemisulfate
3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
Other Name: Proflavine
Experimental: Proflavine hemisulfate
confocal imaging using contrast agent proflavine
Drug: Fluorescein
fluorescent contrast agent, Fluorescein 5ml


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patient 18 years or older
  • colonoscopy for screening or surveillance of polyps or disease of colon
  • anoscopy because of suspected or known anal dysplasia or neoplasia

Exclusion Criteria:

  • patient unable to provide informed consent
  • patient found unfit for standard colonoscopy or anoscopy with biopsies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01384695

United States, New York
Mount Sinai Medical Center
New York, New York, United States, 10029
Sponsors and Collaborators
Anandasabapathy, Sharmila, M.D.
Principal Investigator: Sharmila Anandasabapathy, M.D. Mt. Sinai School of Medicine
  More Information

Responsible Party: Anandasabapathy, Sharmila, M.D. Identifier: NCT01384695     History of Changes
Other Study ID Numbers: GCO# 09-0696 Project 1
Study First Received: June 28, 2011
Last Updated: January 8, 2016

Keywords provided by Anandasabapathy, Sharmila, M.D.:
Barrett's esophagus
confocal microendoscopy

Additional relevant MeSH terms:
Barrett Esophagus
Digestive System Abnormalities
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Anti-Infective Agents, Local
Anti-Infective Agents processed this record on August 23, 2017